GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
申请人:Shanghai LaiYi Center For Biopharmaceutical
R&D Co., Ltd.
公开号:EP3763728A1
公开(公告)日:2021-01-13
The present invention discloses glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I),
The present invention also provides a preparation method for and an application of the glycopeptide compounds. Upon testing, compared with a second-generation glycopeptide drug oritavancin, the glycopeptide antibiotic compounds have higher inhibition activity on drug-resistant bacterial strains, especially MRSA or VRE. Further testing shows that most of the glycopeptide compounds have safety higher than that of oritavancin and can be prepared into drugs for treating or preventing diseases caused by various bacterial infections, such as skin and soft tissue infections, meningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, and empyema,
本发明公开了具有抗耐药性细菌活性的糖肽化合物,符合通式(I)所代表的糖肽化合物、
本发明还提供了糖肽化合物的制备方法和应用。经测试,与第二代糖肽药物奥利他万星(oritavancin)相比,糖肽抗生素化合物对耐药菌株,尤其是 MRSA 或 VRE 具有更高的抑制活性。进一步的测试表明,大多数糖肽化合物的安全性高于奥利他万星,可以制备成药物,用于治疗或预防各种细菌感染引起的疾病,如皮肤和软组织感染、脑膜炎、败血症、肺炎、关节炎、腹膜炎、支气管炎和肺水肿、